Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Small Molecules
Filter     Order     Display # 
Date Item Title Hits
12 Mar 2010 FDA Approves Five-Day Dosing Regimen for Dacogen 46
12 Mar 2010 GlaxoSmithKline receives marketing authorisation in the EU for Revolade (eltrombopag) 32
12 Mar 2010 Sanofi-aventis and Bristol-Myers Squibb Announce Important Updates to PLAVIX U.S. Prescribing Information 32
12 Mar 2010 TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints 88
12 Mar 2010 Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development 46
11 Mar 2010 Request for re-examination of ceftobiprole submitted to CHMP 43
11 Mar 2010 Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint 45
11 Mar 2010 Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development 32
11 Mar 2010 Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 33
11 Mar 2010 PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010 29
11 Mar 2010 Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results 29
11 Mar 2010 Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies 35
10 Mar 2010 Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche 49
10 Mar 2010 Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia 58
10 Mar 2010 Limerick BioPharma Announces Positive Phase 1a Data for LIM-0705 47
10 Mar 2010 Cempra Announces the Completion of Phase 1 Studies for CEM-101, a Next-Generation Macrolide 46
10 Mar 2010 BioAlliance Announces Positive Preliminary Results in the First Phase I Clinical Trial of fentanyl Lauriad 44
09 Mar 2010 INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 53
09 Mar 2010 Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease 51
09 Mar 2010 Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53) 87
09 Mar 2010 FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis 44
09 Mar 2010 Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction 53
09 Mar 2010 Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 45
09 Mar 2010 Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury 35
09 Mar 2010 Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies 43
09 Mar 2010 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program 42
08 Mar 2010 Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute for Development of Further Next-Generation Class II-Selective HDAC Inhibitor Compounds 5
08 Mar 2010 NeuroSearch announces new findings from the MermaiHD Phase III study supporting potential disease modifying properties of Huntexil 42
08 Mar 2010 RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer 44
08 Mar 2010 Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer 47
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 8113

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics